The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans

Creative Commons License

Sadullahoglu C., Dere Y., Rezanko Atasever T., Tunakan Oztop M., Karaaslan O.

TURKISH JOURNAL OF PATHOLOGY, cilt.33, sa.3, ss.223-227, 2017 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5146/tjpath.2017.01402
  • Dergi Adı: TURKISH JOURNAL OF PATHOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.223-227
  • Anahtar Kelimeler: Dermatofibroma, Dermatofibrosarcoma protuberans, CD34, D2-40, Podoplanin, PODOPLANIN, EXPRESSION, TUMORS, IMMUNOREACTIVITY, BENIGN
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Objective: Dermatofibroma (DF) is a benign fibrohistiocytic tumor whereas dermatofibrosarcoma protuberans (DFSP) has intermediate malignant potential. CD34 is the most commonly used antibody in differentiating these tumors. Various studies have stated the rates of D2-40 expression as 0-50% in DFSPs and 86-100% in DFs. Our aim in this study was to determine the expression of CD34 and D2-40 in DFs and DFSPs and the possible use of D2-40 in the differential diagnosis of these lesions.